TLSA

Company Overview — What Does Tiziana Life Sciences Ltd Do?

Tiziana Life Sciences plc, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology, inflammation, and infectious diseases. Its lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. The company is also developing Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients. It has a collaboration agreement with FHI Clinical to conduct a Phase 2 clinical trials for treating hospitalized severe COVID-19 patients with intranasal foralumab. The company was incorporated in 1998 and is based in London, the United Kingdom. Tiziana Life Sciences Ltd (TLSA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Gabriele Marco Antonio Cerrone and employs approximately 8 people. With a market capitalization of $159M, TLSA is one of the notable companies in the Healthcare sector.

Tiziana Life Sciences Ltd (TLSA) Stock Rating — Reduce (April 2026)

As of April 2026, Tiziana Life Sciences Ltd receives a Reduce rating with a composite score of 34.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.TLSA ranks #3,665 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Tiziana Life Sciences Ltd ranks #601 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TLSA Stock Price and 52-Week Range

Tiziana Life Sciences Ltd (TLSA) currently trades at $1.16. The stock lost $0.10 (7.9%) in the most recent trading session. The 52-week high for TLSA is $2.60, which means the stock is currently trading -55.4% from its annual peak. The 52-week low is $0.73, putting the stock 58.9% above its annual trough. Recent trading volume was 341K shares, suggesting relatively thin trading activity.

Is TLSA Overvalued or Undervalued? — Valuation Analysis

Tiziana Life Sciences Ltd (TLSA) carries a value factor score of 28/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 40.73x, versus the sector average of 2.75x.

At current multiples, Tiziana Life Sciences Ltd trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Tiziana Life Sciences Ltd Profitability — ROE, Margins, and Quality Score

Tiziana Life Sciences Ltd (TLSA) earns a quality factor score of 30/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -1205.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -420.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TLSA Debt, Balance Sheet, and Financial Health

Tiziana Life Sciences Ltd has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $0. Cash and equivalents stand at $4M.

TLSA has a beta of 0.90, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Tiziana Life Sciences Ltd is 33/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Tiziana Life Sciences Ltd Revenue and Earnings History — Quarterly Trend

In TTM 2026, Tiziana Life Sciences Ltd reported revenue of $0 and earnings per share (EPS) of $-0.11. Net income for the quarter was $-12M. Operating income came in at $-16M.

In FY 2024, Tiziana Life Sciences Ltd reported revenue of $0 and earnings per share (EPS) of $-0.11. Net income for the quarter was $-12M. Operating income came in at $-16M.

In FY 2023, Tiziana Life Sciences Ltd reported revenue of $0 and earnings per share (EPS) of $-0.17. Net income for the quarter was $-18M. Operating income came in at $-18M.

In FY 2022, Tiziana Life Sciences Ltd reported revenue of $0 and earnings per share (EPS) of $-0.15. Net income for the quarter was $-15M. Operating income came in at $-15M.

Over the past 8 quarters, Tiziana Life Sciences Ltd has experienced revenue contraction from $0 to $0. Investors analyzing TLSA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TLSA Dividend Yield and Income Analysis

Tiziana Life Sciences Ltd (TLSA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TLSA Momentum and Technical Analysis Profile

Tiziana Life Sciences Ltd (TLSA) has a momentum factor score of 29/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 51/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 62/100 reflects moderate short selling activity.

TLSA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Tiziana Life Sciences Ltd (TLSA) ranks #601 out of 838 stocks based on the Blank Capital composite score. This places TLSA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TLSA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TLSA vs S&P 500 (SPY) comparison to assess how Tiziana Life Sciences Ltd stacks up against the broader market across all factor dimensions.

TLSA Next Earnings Date

No upcoming earnings date has been announced for Tiziana Life Sciences Ltd (TLSA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TLSA? — Investment Thesis Summary

The quantitative profile for Tiziana Life Sciences Ltd suggests caution. The quality score of 30/100 flags below-average profitability. The value score of 28/100 indicates premium valuation. Momentum is weak at 29/100, a headwind for near-term performance. High volatility (stability score 33/100) increases portfolio risk.

In summary, Tiziana Life Sciences Ltd (TLSA) earns a Reduce rating with a composite score of 34.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TLSA stock.

Related Resources for TLSA Investors

Explore more research and tools: TLSA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TLSA head-to-head with peers: TLSA vs AZN, TLSA vs SLGL, TLSA vs VMD.